FarmavitaR+

1. Fibromyalgia
(Regulatory Affairs/Regulatory Affairs News)

... downgraded its sales forecast for Xyrem (sodium oxybate, Jazz Pharma and UCB). This stems from a newly-highlighted concern over the robustness of the Phase III development program design and the negative ...

2. Biosimilars: Key developments in the regulatory environment
(Reports/Product Report)

... opportunities have been created for generics companies in the biopharmaceutical market, which according to IMS data was valued at $85.9 billion in 2007. Conservative projections estimate that sales of ...

3. The Top 10 Biosimilar Players
(Reports/Market Report)

... market are identified and the leading companies in this sector are profiled in detail. This report examines the portfolio sales performances, pipelines and growth strategies of each of the top 10 biosimilars ...

4. Biosimilars expansion in the USA
(Biosimilars/Biosmimilars)

... market will contribute to almost half of all biosimilars market volume and sales through 2012, beyond which it will be overtaken by the US. The US market represents the greatest opportunity for the emerging ...

5. Generic Benchmarking
(Reports/Market Report)

Generic Benchmarking: Brand Erosion at Patent Expiry Not only is Pharma facing a continued slow down in sales growth in the seven major markets, but erosion of branded drugs by generics follow patent ...

6. Biosimilars
(Reports/Market Report)

... is unlikely to experience significant biosimilar incursion through the forecast period, contributing at most 1% to total seven major market volume sales in 2019. Read more...  ...

7. Russia’s Emerging OTC Market Holds Problems As Well As Promise
(Regulatory Affairs/Europe not-EU)

... 17, 2008, p. 9). Novartis also increased its OTC sales by 14 percent in early fiscal 2008 by expanding in Russia and Latin America, the Swiss firm said (2"The Tan Sheet April 28, 2008, p. 14). In a ...

8. Bayer Schering Pharma AG
(Reports/Company Report)

... strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated ...

9. Wyeth
(Reports/Company Report)

... and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative ...

10. Johnson & Johnson
(Reports/Company Report)

... and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative ...

11. AstraZeneca plc
(Reports/Company Report)

... portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative ...

12. Schering-Plough Corporation
(Reports/Company Report)

... strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated ...

13. Amgen Inc.
(Reports/Company Report)

... and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative ...

14. Novo Nordisk A/S
(Reports/Company Report)

... portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative ...

15. Bristol-Myers Squibb Co.
(Reports/Company Report)

... strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated ...

16. Pfizer Inc.
(Reports/Company Report)

... and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative ...

17. Genentech Inc.
(Reports/Company Report)

... and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative ...

18. Chugai Pharmaceutical Co. Ltd
(Reports/Company Report)

... company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually ...

19. Boehringer Ingelheim GmbH
(Reports/Company Report)

... strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated ...

20. Abbott Laboratories
(Reports/Company Report)

... strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated ...